Will taking Ivosidenib easily lead to an increase in uric acid in the body?

Ivosidenib is an oral drug targeting IDH1 mutations. It is mainly used to treat patients with acute myeloid leukemia (AML) who carry IDH1 gene mutations. In recent years, with the widespread use of this drug, some patients have experienced elevated uric acid levels in their bodies during treatment, which has attracted clinical attention. Elevated uric acid is mainly related to tumor lysis syndrome (TLS), which is a phenomenon in which tumor cells release large amounts of cellular contents after rapid death, leading to an increase in uric acid, potassium, phosphorus and other substances in the blood.

During ivonib treatment, especially in patients with higher disease burden, rapid tumor cell necrosis may lead to increased uric acid production, leading to hyperuricemia. If not treated in time, high uric acid may cause damage to kidney function and even induce uric acid stones or kidney failure. Therefore, clinicians usually assess patients' renal function and uric acid levels before starting medication and closely monitor relevant indicators during treatment.

To prevent and control increases in uric acid during ivosidenib treatment, common practices include adding sufficient fluids to promote urinary excretion, using urate-lowering drugs such as allopurinol or febuxostat, and adjusting drug dosage as needed. During treatment, patients should pay attention to regular review of blood biochemical indicators, especially uric acid and renal function, and communicate with the doctor promptly if any abnormalities are found so that appropriate measures can be taken.

Overall, ivonib does have the risk of causing an increase in uric acid in the body, especially in patients with larger tumor loads. Reasonable prevention and monitoring measures can effectively reduce this risk and ensure patient medication safety. Patients and family members should understand relevant information and actively cooperate with doctors to standardize management to ensure smooth treatment.

Reference materials:https://www.drugs.com